translation agency

Gay Men's Health Crisis
DRUG WATCH: Japanese Company Invests in Vertex
David Gold
May 1, 1993
GMHC Treatment Issues 1993 May 1; 7(5): 11

Kissei, a Japanese drug company, paid $20 million for Asian marketing rights to Vertex's HIV protease inhibitors. Vertex has several protease compounds in preclinical development. Vertex claims its protease compounds are more potent than Abbott's and more bioavailable than Roche's.

Copyright (c) 1993 - GMHC Treatment Issues. Noncommercial reproduction encouraged. Distributed by AEGIS, your online gateway to a world of people, knowledge, and resources. Direct Dial: v.34+: 714.248.2836; v.120/ISDN: 714.248.0433 Internet: telnet:aegis.com www: www.aegis.com

www.aegis.org